Onchilles Pharma
PrivateLast Round
Series A
Extension
Nov 7, 2025
Total Funding Raised
$36.22M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Onchilles Pharma operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series A Extension round in November 2025.
Onchilles Pharma is a biotechnology company that develops first-in-class cytotoxic therapeutics designed to selectively kill cancer cells while preserving and activating immune function by harnessing the ELANE pathway.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Onchilles Pharma Comparables
Compare Onchilles Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avilar Therapeutics | 86% | |
| Lycia Therapeutics | 85% | |
| Plexium | 83% |
For institutional investors. Book with your work email.
Onchilles Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 7, 2025 | ||||
| Series A | Jun 10, 2021 | ||||
| Seed | Jul 10, 2020 | ||||
| Grant | Dec 6, 2017 |
For institutional investors. Book with your work email.
Onchilles Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCM Ventures | Series A Extension |
| Lincoln Park Capital | Series A Extension |
| Kennedy Lewis Investment Management | Series A Extension |
| LYZZ Capital | Series A Extension, Series A |
| InVivium Capital | Series A Extension |
| NuFund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 76% MoM, reaching 1.5K.
- Apr 21, 2026
Presenting a trial in progress poster at ASCO Annual Meeting.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 6, 2026
Onchilles Pharma, Inc. reports preliminary clinical findings from its Phase 1/2 trial of intratumoral N17350 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer in California.
For institutional investors. Book with your work email.
Onchilles Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Onchilles Pharma's valuation, stock price, and market status.
Is Onchilles Pharma a public or private company?
Onchilles Pharma is a private company.
What is the current stock price of Onchilles Pharma?
Onchilles Pharma is a private company, so its shares have no public market price. Caplight tracks Onchilles Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Onchilles Pharma worth (valuation)?
Valuation information for Onchilles Pharma is not publicly available.
Can I buy Onchilles Pharma stock?
Onchilles Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Onchilles Pharma's last funding round?
Onchilles Pharma's most recent funding round was Series A Extension on November 7, 2025.
Who are the main investors in Onchilles Pharma?
Key investors in Onchilles Pharma include LYZZ Capital.
Will Onchilles Pharma IPO soon?
No public IPO plans have been announced for Onchilles Pharma.
How can I track Onchilles Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Onchilles Pharma's shares on secondary markets.